12月20日，中国北京同仁堂（集团）有限责任公司发布声明，针对近日"南极磷虾油"产品造假事件向消费者和社会各界致歉，并宣布启动"零容忍品牌严管 专项行动"。 声明中指出，北京同仁堂将派专项工作组到四川，对涉事产品开展全面深入核查，坚决一查到底。责令并监督涉事经销主体四川健康立即下架涉事产品，严 格按照监管部门要求依法依规对消费者进行赔偿。 北京同仁堂依法追究四川健康、哈博药业及相关电商平台的商标侵权等责任。对其违法使用"北京同仁堂"字样，误导消费者判断，损害消费者合法权益的行 为追究法律责任。对四川健康及其控股股东健康药业等单位在经营、管理、监督环节存在的问题开展问责，严肃追究相关人员责任。 同时，北京同仁堂全面排查品牌使用中的违法违规行为，对集团各级企业的品牌使用情况进行拉网式核查。全面开展品牌清理行动，坚决清理"擦边"使 用"同仁堂"字号、商标使用不规范等行为，严格规范品牌管理体系。全面规范电商平台授权店铺标识，严格使用"同仁堂"双龙图案商标，主动引导消费者准 确识别正规购买渠道。 近日，上海市消保委发布15款南极磷虾油产品比较检测结果，其中一款标称"北京同仁堂99%高纯南极磷虾油"的产品引发关注。 面对 ...

据北京同仁堂官微，针对近日有关"南极磷虾油"的舆论关注，北京同仁堂集团高度重视、深感痛心，对 因此给消费者造成的权益损害，向广大消费者和社会各界致以最诚恳的歉意！同仁堂集团立即开展零容 忍品牌严管专项行动，已采取如下措施：一、派专项工作组到四川，对涉事产品开展全面深入核查，坚 决一查到底。二、责令并监督涉事经销主体四川健康立即下架涉事产品，严格按照监管部门要求依法依 规对消费者进行赔偿。三、依法追究四川健康、哈博药业及相关电商平台的商标侵权等责任。对其违法 使用"北京同仁堂"字样，误导消费者判断，损害消费者合法权益的行为追究法律责任。四、对四川健康 及其控股股东健康药业等单位在经营、管理、监督环节存在的问题开展问责，严肃追究相关人员责任。 ...

每经AI快讯，12月20日，北京同仁堂通过官微发布声明称，针对近日有关"南极磷虾油"的舆论关注，北 京同仁堂集团高度重视、深感痛心，对因此给消费者造成的权益损害，向广大消费者和社会各界到以最 诚恳的歉意！同仁堂集团立即开展零容忍品牌严管专项行动，已采取如下措施：一、派专项工作组到四 川，对涉事产品开展全面深入核查，坚决一查到底。二、责令并监督涉事经销主体四川健康立即下架涉 事产品，严格按照监管部门要求依法依规对消费者进行赔偿。三、依法追究四川健康、哈博药业及相关 电商平台的商标侵权等责任。对其违法使用"北京同仁堂"字样，误导消费者判断，损害消费者合法权益 的行为追究法律责任。四、对四川健康及其控股股东健康药业等单位在经营、管理、监督环节存在的问 题开展问责，严肃追究相关人员责任。 北京同仁堂集团声明：全力保护消费者权益 开展品牌严管专项行动 二、全面开展品牌清理行动,坚决清理"擦边"使用"同仁堂"字号、商标使用不规范 等行为,严格规范品牌管理体系。 三、全面规范电商平台授权店铺标识,严格使用"同仁堂"双龙图莱商标,主动引导消 费者准确识别正规购买渠道。 中国北京同仁学官微 2025年12月20日 08:04 ...

转自：北京日报客户端 北京同仁堂集团声明：全力保护消费者权益 开展品牌严管专项行动 针对近日有关"南极磷虾油"的舆论关注，北京同仁堂集团高度重视、深感痛心，对因此给消费者造成的 权益损害，向广大消费者和社会各界致以最诚恳的歉意！同仁堂集团立即开展零容忍品牌严管专项行 动，已采取如下措施： 一、派专项工作组到四川，对涉事产品开展全面深入核查，坚决一查到底。 四、对四川健康及其控股股东健康药业等单位在经营、管理、监督环节存在的问题开展问责，严肃追究 相关人员责任。 为进一步保护消费者权益，强化品牌保护责任，同仁堂集团同时开展以下工作： 一、全面排查品牌使用中的违法违规行为，对集团各级企业的品牌使用情况进行拉网式核查。 二、全面开展品牌清理行动，坚决清理"擦边"使用"同仁堂"字号、商标使用不规范等行为，严格规范品 牌管理体系。 三、全面规范电商平台授权店铺标识，严格使用"同仁堂"双龙图案商标，主动引导消费者准确识别正规 购买渠道。 "同仁堂"品牌创立356年来，始终离不开广大消费者的支持和厚爱。我们心怀感恩，诚恳接受社会各界 的监督与批评，愿意与大家一道，共同守护好"同仁堂"金字招牌，以实际行动维护"同仁堂"的品牌 ...

北京同仁堂发布致歉声明称，针对近日有关"南极磷虾油"的舆论关注，集团对因此给消费者造成的权益 损害，向广大消费者和社会各界致以最诚恳的歉意。同仁堂集团立即开展零容忍品牌严管专项行动，已 采取如下措施：派专项工作组到四川，对涉事产品开展全面深入核查，坚决一查到底；责令并监督涉事 经销主体四川健康立即下架涉事产品，严格按照监管部门要求依法依规对消费者进行赔偿；依法追究四 川健康、哈博药业及相关电商平台的商标侵权等责任。对其违法使用"北京同仁堂"字样，误导消费者判 断，损害消费者合法权益的行为追究法律责任。 北京同仁堂集团声明：全力保护消费者权益 开展品牌严管专项行动 中国北京同仁堂官微 2025年12月20日 08:04 北京 针对近日有关"南极磷虾油"的奥论关注,北京同仁堂集团高度重视、深感痛心,对因 此给消费者造成的权益损害,向广大消费者和社会各界致以最诚恳的歉意!同仁堂集团立即 开展零容忍品牌严管专项行动,已采取如下措施: 一、派专项工作组到四川,对涉事产品开展全面深入核查,坚决一查到底。 二、全面开展品牌演理行动,坚决清理"擦边"使用"同仁堂"字号、商标使用不规范 等行为,严格规范品牌管理体系。 三、全面 ...

Core Viewpoint - The investor research event held by Tongrentang Technology showcased the company's commitment to modernizing traditional Chinese medicine while maintaining its heritage and quality standards [1][3]. Group 1: Production and Technology - The production line at Tongrentang Technology employs automated and connected processes, ensuring a standardized, controllable, and efficient production of traditional Chinese medicine products [3]. - The company is actively investing in new equipment and technologies to build a modern intelligent manufacturing system for traditional Chinese medicine, aiming for high-quality, traceable products [3]. Group 2: Management Communication - During the event, the management team, led by General Manager Zhang Chunyou, engaged in in-depth discussions with investors regarding the company's strategic direction, core product layout, capacity enhancement, and future growth opportunities [4]. - The management emphasized the systemic development opportunities in the traditional Chinese medicine industry, driven by national health strategies and policies, and the company's commitment to deepening its presence in this field [4]. Group 3: Investor Relations - The event served as a platform for investor relations management, highlighting the importance of transparent and proactive communication between the company and its investors [5]. - Tongrentang Technology aims to create an open and inclusive investor relations ecosystem, reflecting its strategic determination and commitment to product value [5].

Core Viewpoint - The investor research event held by Tong Ren Tang Technology showcased the company's commitment to modernizing traditional Chinese medicine while maintaining its heritage and quality standards [1][2]. Group 1: Production and Innovation - The production line at Tong Ren Tang Technology employs automated and connected processes, ensuring efficiency and quality in the manufacturing of traditional Chinese medicine products [2]. - The company is focused on upgrading its production capabilities and implementing new technologies to create a modern intelligent manufacturing system for traditional Chinese medicine [2]. - The goal is to ensure that every pill produced meets high-quality standards and is traceable, embodying the spirit of Tong Ren Tang in a modern factory setting [2]. Group 2: Management Communication and Strategy - During the event, the management team, led by General Manager Zhang Chunyou, engaged in detailed discussions with investors regarding the company's operational strategy, product positioning, and future growth opportunities [3]. - The management emphasized the systemic development opportunities in the traditional Chinese medicine industry, driven by national health strategies and policies [3]. - Tong Ren Tang Technology aims to leverage its brand, technology, and quality advantages to deepen its focus on traditional Chinese medicine and explore new growth avenues in health management [3]. Group 3: Investor Relations - The research event served as a platform for enhancing investor relations, with the management team expressing the importance of transparent communication with investors [4]. - The company is committed to maintaining an open and inclusive investor relations ecosystem, reflecting its strategic determination and proactive approach in the industry [4]. - Continuous and transparent communication is seen as a vital bridge connecting the company with long-term value investors [4].

Core Viewpoint - The recent incident involving Antarctic krill oil with zero phospholipid content has tarnished the reputation of the "Tong Ren Tang" brand, highlighting ongoing issues with brand and trademark management within the Tong Ren Tang Group [1][3]. Group 1: Incident Overview - The Antarctic krill oil in question was produced by Anhui Habao Pharmaceutical and distributed by Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical, which is not a subsidiary of the publicly listed Tong Ren Tang [3]. - The product used the "Tong Ren Tang" trademark, which is owned by the Tong Ren Tang Group, leading to public confusion and backlash against the listed company [3][4]. - The company clarified that it does not hold any equity or investment rights in the implicated Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical [3]. Group 2: Brand Management Issues - The incident underscores the chaotic brand authorization within the Tong Ren Tang Group, which could lead to further issues if not addressed [5]. - The krill oil product prominently featured the "Beijing Tong Ren Tang" label, raising concerns about brand misuse and the similarity to the "Tong Ren Tang" double-dragon trademark [5][6]. - The Tong Ren Tang Group controls over 500 enterprises and has a complex business structure, which complicates product quality and brand management [6]. Group 3: Historical Context - Tong Ren Tang was founded in 1669 and has a long history of serving the imperial court, which has contributed to its prestigious reputation [7]. - The brand has faced legal challenges in the past, including a notable trademark infringement case with Tianjin Tong Ren Tang, which has led to ongoing litigation and eventual acquisition plans [9][10]. - Multiple entities using the "Tong Ren Tang" name across different regions complicate brand management and increase the risk of brand dilution [12].

Core Insights - The investor research event held on December 16 at Tong Ren Tang Technology Development Co., Ltd. showcased the company's modernization efforts and commitment to traditional craftsmanship in the context of its transformation [1] Group 1: Production and Technology - The production line at Tong Ren Tang employs automated and connected processes, ensuring a seamless workflow from pill production to packaging, highlighting the integration of traditional methods with modern technology [4] - The company aims to establish a modern intelligent manufacturing system for traditional Chinese medicine, ensuring that each pill maintains high quality and traceability [4] Group 2: Management Communication - During the event, the management team, led by General Manager Zhang Chunyou, engaged in detailed discussions with investors regarding the company's operational strategy, core product layout, capacity enhancement, and future growth potential [4] - The management emphasized the importance of transparent communication with investors to convey the company's cultural values, operational logic, and strategic planning [5] Group 3: Industry Context - The Chinese medicine industry is perceived to be entering a systematic development opportunity, supported by national health strategies and policies promoting traditional medicine [5] - Tong Ren Tang is positioned to leverage its brand, technology, and quality systems to deepen its engagement in the traditional medicine sector and explore new growth avenues [5]

2025.12. 18 作者 | 第一财经 钱童心 "同仁堂"涉嫌磷虾油造假事件还在进一步发酵。北京同仁堂股份有限公司（同仁堂，600085.SH） 日前发布澄清公告称，同仁堂股份未直接或间接持有南极磷虾油相关报道中提及的四川健康药业任何 股权及投资权益，四川健康药业不属于自己下属子企业。北京同仁堂健康药业股份有限公司为北京同 仁堂（四川）健康药业有限公司的控股股东。 不过，对于同仁堂这种急于"撇清关系"的说法，相关律师认为，这是企业的"文字游戏"。"北京同仁 堂（四川）健康药业有限公司虽然不是上市公司北京同仁堂股份有限公司的子公司，但却是其关联公 司。"上海大邦律师事务所合伙人游云庭对第一财经记者表示，"两家公司相当于是叔侄关系，共同 的上级公司是商标权人北京同仁堂集团公司，虽然上市公司的下属公司没出问题，但整个品牌暴露在 风险之下。" 近日，上海市消保委对"同仁堂"相关磷虾油生产商安徽哈博药业有限公司和经销商北京同仁堂（四 川）健康药业有限公司进行约谈后，"四问同仁堂"。 上海市消保委提出，相关磷虾油产品极低的采购价也令人迷惑。该产品网上售价为69.9元一瓶，然 而产品供货价仅为3元多一瓶，也间接佐证了产 ...